Comments
Glenmark Pharmaceuticals has received tentative nod from the US health regulator for Clobetasol Propionate foam, used to treat inflammation and itching caused by common skin conditions like eczema.
Glenmark Pharmaceuticals Inc USA has been granted tentative approval by the United States Food & Drug Administration for Clobetasol Propionate Foam, 0.05 per cent (emulsion formulation), the company said in a BSE filing.
The approved product is a generic version of Mylan Pharmaceuticals Inc’s Olux-E Foam, 0.05 per cent. Quoting IQVIA sales data for the 12-month period ended September 2018, Glenmark Pharmaceuticals said, Olux-E Foam achieved annual sales of around $13.2 million.
The company’s current portfolio consists of 144 products authorised for distribution in the US market and 55 abbreviated new drug applications (ANDAs) pending approval with the USFDA. Shares of Glenmark Pharmaceuticals were trading 0.06 per cent lower at Rs 637.45 apiece on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.